Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Chugai Pharma (4519 JP): Hemlibra, Actemra Hold the Show Together, Orforglipron Is The Next Big Draw

Chugai Pharma (4519 JP): Hemlibra Steady, Actemra Shine, Outlicensed Drug and New Launches Key

Chugai Pharma (4519 JP): Hemlibra Drive 1Q26, 2026 Guidance Reiterated, Orforglipron Launched in US

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/chugai-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:4489:1" rel="noopener">Chugai Pharmaceutical (4519 JP)</a> reported a rise of 15% YoY in revenue to ¥663.3B. Mainstay alongside new products help maintain growth momentum in both domestic and overseas market.</li>
<li>2026 guidance reiterated. Revenue expected to increase 7% YoY. Core profit numbers expected to increase by 7.5% YoY each. Achieved almost 43-46% of their 2026 headline guidance numbers.</li>
<li>Although Chugai is still hugely dependent on Hemlibra export, new launches are slowly gaining momentum. Moreover, new breakthrough products like orforglipron will help provide some traction to the growth momentum.</li>
</ul>



Chugai Pharmaceutical (4519 JP) reported a rise of 15% YoY in revenue to ¥663.3B. Mainstay alongside new products help maintain growth momentum in both domestic and overseas market.
2026 guidance reiterated. Revenue expected to increase 7% YoY. Core profit numbers expected to increase by 7.5% YoY each. Achieved almost 43-46% of their 2026 headline guidance numbers.
Although Chugai is still hugely dependent on Hemlibra export, new launches are slowly gaining momentum. Moreover, new breakthrough products like orforglipron will help provide some traction to the growth momentum.


Chugai Pharma (4519 JP): Guidance Reiterated As Both Overseas & Domestic Grow in 1H26